About Geneoscopy
Geneoscopy is a Healthcare company based in St. Louis (United States) founded in 2015. Non-invasive biomarker tests for colorectal cancer are developed. Geneoscopy has raised $218.95 million across 6 funding rounds from investors including LabCorp, Mercy Health and Bio Rad. Geneoscopy offers products and services including seRNA Technology Platform and Stool-based Screening Test. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is Geneoscopy Inc. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Geneoscopy was founded in 2015 and is headquartered in St. Louis, United States. Non-invasive diagnostic tests for colorectal cancer are developed within the biotechnology sector. Stool samples are examined for a panel of mRNA biomarkers through a proprietary algorithm to identify the disease. The primary assay is designed for screening patients potentially needing colonoscopy procedures, with operations centered on advancing biomarker-based diagnostics.
- Headquarters St. Louis, United States
- SectorsHealthcare
- Email••••••••
- Website geneoscopy.com
- Social LinkedIn X Facebook Instagram
- Legal Name Geneoscopy Inc.
- Total Equity Funding$218.95M (USD)
in 6 rounds
- Latest Funding Round$105M (USD), Series C
Jan 2025
- InvestorsLabCorp
& 16 more
Products & Services of Geneoscopy
Geneoscopy offers a comprehensive portfolio of products and services, including seRNA Technology Platform and Stool-based Screening Test.
Noninvasive platform for detecting colorectal cancer and GI diseases
Test for early detection of gastrointestinal conditions using RNA analysis
Funding Insights of Geneoscopy
Geneoscopy has successfully raised a total of $218.95M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $105 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $218.95M
- Total Rounds 6
- Last Round Series C — $105M
- First Round $50,000
(Jun 2016)
- Investors Count 17
All 6 funding rounds of Geneoscopy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $105M | Series C | – | Bio Rad | |
| Nov 2021 | Debt – Conventional | – | – | ||
| Nov 2021 | $105M | Series B | – | LightChain Capital, NT Investments | |
| Sep 2019 | $7.95M | Series A | – | Cultivation Capital | |
| Apr 2018 | $1M | Seed | – | Missouri Technology, Billiken Angels Network | – |
| Jun 2016 | $50,000 | Grant | – | – |
17 investors in total: 17 institutional.
Investors in Geneoscopy
Geneoscopy has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include LabCorp, Mercy Health and Bio Rad.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Venture capital fund focused on early-stage life science companies | lightchain-capital.com | St. Louis, United States | ||
African project coordination is provided by NT Investment Group. | 2022 | ntinvest.group | Mbabane, Kingdom of Eswatini | |
Early-stage tech companies are funded by this venture capital firm. | cultivationcapital.com | St. Louis, United States | ||
Diversified debt funding is provided for growth capital opportunities. | innovatuscp.com | New York, United States | ||
Venture capital and acceleration are provided to life science startups. | biogeneratorventures.com | St. Louis, United States | ||
Tech companies focused VC firm operating across Missouri | missouritechnology.com | Jefferson City, United States | ||
Angel investing network focused on regional economic impact. | 2010 | billikenangels.com |
Investor details for Geneoscopy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Geneoscopy
34 people are tracked at Geneoscopy (12 in leadership, 4 in board & advisors, 18 in team).
| Name | Role | Group |
|---|---|---|
Erica Barnell | Chief Science Officer & Co-Founder | Leadership |
Gary Gallimore | VP, Software Engineering & Information Technology | Leadership |
Andrew Barnell | CEO & Co-Founder | Leadership |
Rachel Carbaugh | Head of People | Leadership |
Marshall Phares | Director Of Finance | Leadership |
Judy Pretto | Director Marketing Communications | Leadership |
Eric Duncavage, MD | Medical Director | Leadership |
Elizabeth Wurtzler | Director of Research and Development | Leadership |
Julie La Rocca,RAC,CHPC,CHC | VP, Quality Assurance & Regulatory Affairs | Leadership |
Nikki Durrant | Director Of Software QA | Leadership |
Eric Malec | Sr. Director, HCP Marketing | Leadership |
Matthew Schnell | Director Of Quality Assurance | Leadership |
James Merselis | Board Member | Board & advisors |
Bobby W. Sandage Jr. | Board Member | Board & advisors |
Drew Dennison | Board Member | Board & advisors |
Najeeb Thomas | Board Member | Board & advisors |
Julie LaRocca | Svp, Quality Assurance & Regulatory Affairs | Team |
Ismail Adiputra | Software QA Engineer | Team |
Gene L. Garcia, PhD | Quality Engineer | Team |
James H. | Devops Engineer | Team |
14 more people are available in the full profile.
Complete people profiles for Geneoscopy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Geneoscopy
3 dated milestones of Geneoscopy across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Geneoscopy is founded.
- Funding First funding round of $50K.
- Funding Latest funding round, Series C, of $105.0M.
Competitors of Geneoscopy
Geneoscopy has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Geneoscopy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Geneoscopy
The website of Geneoscopy (geneoscopy.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 29.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Geneoscopy (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Geneoscopy
Complete news archive for Geneoscopy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Geneoscopy
Geneoscopy was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Geneoscopy is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Geneoscopy is a funded company, having raised a total of $218.95M across 6 funding rounds to date. The company's 1st funding round was a Grant of $50K, raised on Jun 2016.
Geneoscopy was founded in 2015 and is headquartered in St. Louis, United States. Non-invasive diagnostic tests for colorectal cancer are developed within the biotechnology sector. Stool samples are examined for a panel of mRNA biomarkers through a proprietary algorithm to identify the disease. The primary assay is designed for screening patients potentially needing colonoscopy procedures, with operations centered on advancing biomarker-based diagnostics.
Geneoscopy's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Geneoscopy offers seRNA Technology Platform and Stool-based Screening Test.
Geneoscopy has 17 investors. Key investors include LabCorp, Mercy Health, Bio Rad, Arch Grants, and Petrichor.
Geneoscopy operates through Geneoscopy Inc..